The abstract is read at the publisher; the summary is JClub's.
Microenvironmental PGF2α sensitizes tumors to ferroptosis by binding FSP1 at alanine 295 (A295) and inhibiting its activity, enabling lipid peroxidation accumulation.
- Why it matters: Ferroptosis can enhance cancer treatment and immunotherapy, but microenvironmental lipid metabolites that regulate ferroptotic sensitivity remain unclear.
- What they did: Using single-cell and bulk transcriptomics from immunotherapy cohorts, the prostaglandin pathway was linked to tumor ferroptosis and therapeutic efficacy; screening identified PGF2α as a potent endogenous sensitizer.
- The result: In immunocompetent mice, PGF2α supplementation or FSP1 ablation enhanced tumoral ferroptosis, potentiated CD8+ T cell immunity, and suppressed tumor progression, and a high PGF2α activity-related signature correlated with elevated ferroptosis and improved patient survival.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.